Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474773 | 0.72 | USP30 (0.44) | USP30 | |
| SCHEMBL17113500 | 0.69 | BMPR1B (0.35) | — | |
| SCHEMBL16278505 | 0.69 | — | — | |
| SCHEMBL16278708 | 0.67 | TP53 (0.38) | — | |
| SCHEMBL16278502 | 0.63 | CA12 (0.60) | — | |
| SCHEMBL1449809 | 0.63 | SYK (0.30) | — | |
| SCHEMBL3584991 | 0.61 | ALDH1A1 (0.41) | — | |
| SCHEMBL3595550 | 0.61 | DRD2 (0.55) | — | |
| SCHEMBL16463118 | 0.60 | ADRA2C (0.43) | — | |
| SCHEMBL4008508 | 0.60 | TTR (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-20230310358-A1 | Compositions And Methods For Treating Autism | YAMO PHARMACEUTICALS LLC (US) | 2023-10-05 | — | — | US | disclosed |
| CN-114901272-A | Sustained release preparation | 霍夫曼技术有限责任公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220211650-A1 | SUSTAINED RELEASE FORMULATIONS | HOFFMAN TECHNOLOGIES LLC | 2022-07-07 | — | — | US | disclosed |
| US-20210338619-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | YAMO PHARMACEUTICALS LLC | 2021-11-04 | — | — | US | disclosed |
| EP-3823593-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | Yamo Pharmaceuticals LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3823626-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | Yamo Pharmaceuticals LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112822997-A | Compositions and methods for treating autism | 亚莫制药有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-4271187-A | Substituted phenyl alanine antihypertensive agents | MERCK & CO., INC. (US) | 1981-06-02 | — | — | US | disclosed |
| US-4206216-A | Antihypertensive N-heterocyclicalanines | MERCK & CO., INC. (US) | 1980-06-03 | — | — | US | disclosed |
| US-4170654-A | Antihypertensive compositions containing N-heterocyclicalanines and α- | MERCK & CO., INC. (US) | 1979-10-09 | — | — | US | disclosed |
| US-4160835-A | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid | MERCK & CO., INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4156734-A | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid | MERCK & CO., INC. (US) | 1979-05-29 | — | — | US | disclosed |
| US-4153715-A | Indolyl amino acids useful as antihypertensive agents | MERCK & CO., INC. (US) | 1979-05-08 | — | — | US | disclosed |
| US-4065572-A | Amino acids and esters thereof useful as antihypertensive agents | MERCK & CO., INC. (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310358-A1 | Compositions And Methods For Treating Autism | MECP2, AADAT, CHAT | USP30 775/4885 |
| US-20220211650-A1 | SUSTAINED RELEASE FORMULATIONS | TH, PAH, COMT | USP30 319/4885 |
| US-20210338619-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | MECP2, AADAT, CHAT | USP30 791/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | USP30 1759/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | USP30 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.